Literature DB >> 28498514

Secukinumab re-initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis.

A Blauvelt1, K Reich2, R B Warren3, J C Szepietowski4, B Sigurgeirsson5, S K Tyring6, I Messina7, V Bhosekar8, J Oliver7, C Papavassilis7, J Frueh7, R G B Langley9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28498514     DOI： 10.1111/bjd.15656

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  8 in total

Review 1.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Liz Doney; Corinna Dressler; Camille Hua; Carolyn Hughes; Luigi Naldi; Sivem Afach; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2022-05-23

Review 2.  The Relapse of Psoriasis: Mechanisms and Mysteries.

Authors:  Danning Tian; Yuping Lai
Journal:  JID Innov       Date:  2022-03-09

Review 3.  Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.

Authors:  Jillian Frieder; Dario Kivelevitch; Alan Menter
Journal:  Ther Adv Chronic Dis       Date:  2017-11-16       Impact factor: 5.091

4.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Ignacio Garcia-Doval; Liz Doney; Corinna Dressler; Camille Hua; Carolyn Hughes; Luigi Naldi; Sivem Afach; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2021-04-19

5.  Time to Relapse After Discontinuing Systemic Treatment for Psoriasis: A Systematic Review.

Authors:  Marie Masson Regnault; Jason Shourick; Fatma Jendoubi; Marie Tauber; Carle Paul
Journal:  Am J Clin Dermatol       Date:  2022-04-30       Impact factor: 6.233

6.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.

Authors:  Emilie Sbidian; Anna Chaimani; Sivem Afach; Liz Doney; Corinna Dressler; Camille Hua; Canelle Mazaud; Céline Phan; Carolyn Hughes; Dru Riddle; Luigi Naldi; Ignacio Garcia-Doval; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2020-01-09

7.  Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies.

Authors:  A B Kimball; K A Papp; K Reich; M Gooderham; Q Li; N Cichanowitz; C La Rosa; A Blauvelt
Journal:  Br J Dermatol       Date:  2019-11-19       Impact factor: 9.302

Review 8.  Th2 Modulation of Transient Receptor Potential Channels: An Unmet Therapeutic Intervention for Atopic Dermatitis.

Authors:  Jianghui Meng; Yanqing Li; Michael J M Fischer; Martin Steinhoff; Weiwei Chen; Jiafu Wang
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.